Mode
Text Size
Log in / Sign up

Thymectomy and immunotherapy improve symptoms in a patient with myasthenia gravis and paraneoplastic syndromeRare Nerve Damage Tied to Thymoma Improves After Treatment

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that thymectomy and combined immunotherapy can improve symptoms in myasthenia gravis with paraneoplastic features.

This case report and literature review describes the clinical course of a 53-year-old male presenting with peripheral nerve injury, myasthenia gravis, and invasive thymoma. The patient was also positive for CRMP5/CV2 antibodies in both serum and cerebrospinal fluid, indicating a paraneoplastic neurological syndrome. Electrophysiological findings confirmed multiple peripheral nerve damage and a significant decremental response to low-frequency repetitive nerve stimulation.

The patient underwent a thoracoscopic thymectomy and received a combination of glucocorticoids, intravenous immunoglobulin, and cyclophosphamide. Following this intervention, the patient experienced significant improvement of neurological symptoms and maintained a stable condition during follow-up. Serological testing confirmed the presence of acetylcholine receptor (AChR) and CRMP5/CV2 antibodies.

The authors note that the evidence is limited by the small sample size inherent to a case report. However, they suggest that the combination of paraneoplastic antibody detection and chest imaging is critical for early diagnosis. They conclude that thymectomy combined with standardized immunotherapy can effectively improve clinical symptoms and long-term prognosis in such patients.

How this fits prior evidence

This case report addresses a gap in the management of complex presentations involving both myasthenia gravis and paraneoplastic neurological syndromes. While prior coverage noted that B-cell targeted therapies show durable immune responses in myasthenia gravis, this report highlights the efficacy of surgical intervention (thymectomy) and standard immunotherapy (glucocorticoids, intravenous immunoglobulin, and cyclophosphamide) for patients with concurrent thymoma and specific paraneoplastic antibodies.

Imagine dealing with muscle weakness from myasthenia gravis, only to develop a second, rarer problem: nerve damage triggered by your own immune system. That's what happened to a 53-year-old man whose case is described in a new report. He had myasthenia gravis, an invasive thymoma (a tumor in the chest), and a paraneoplastic neurological syndrome, a condition where the immune system attacks the nervous system, often because of a hidden cancer. His blood and spinal fluid tested positive for two antibodies: one linked to myasthenia gravis (AChR) and one linked to paraneoplastic nerve damage (CRMP5/CV2).

Doctors treated him with a thoracoscopic thymectomy (surgery to remove the thymus through small incisions) plus three immune-suppressing treatments: glucocorticoids, intravenous immunoglobulin, and cyclophosphamide. After treatment, his neurological symptoms improved significantly and his condition stayed stable during follow-up.

This is just one person's story, so we can't say the same approach will work for everyone. The report also doesn't mention side effects or how long he was followed. Still, it adds to a growing understanding that when nerve problems and myasthenia gravis appear together, checking for paraneoplastic antibodies and looking at the chest with imaging can be key to catching a thymoma early. For now, the takeaway is simple: in rare cases like this, combining surgery with standard immunotherapy may help, but every patient is different and decisions should be made with a doctor.

What this means for you:
A single case shows nerve damage linked to thymoma improved after surgery and immune treatment, but it's just one person.

Common questions

What is a paraneoplastic neurological syndrome?

It's a rare condition where the immune system attacks the nervous system, often because of a hidden cancer like a thymoma. In this case, the man had antibodies called CRMP5/CV2 in his blood and spinal fluid, which are linked to this syndrome. Symptoms can include nerve damage and weakness.

How was this patient treated?

He had a thoracoscopic thymectomy to remove his thymoma, plus three immune-suppressing treatments: glucocorticoids, intravenous immunoglobulin, and cyclophosphamide. After treatment, his neurological symptoms improved significantly and his condition stayed stable during follow-up.

Does this treatment work for everyone with similar symptoms?

We don't know. This is a single case report, so the results can't be generalized to a broader population. What worked for this one man may not work for others. If you have similar symptoms, talk to your doctor about the best approach for you.

Were there any side effects from the treatment?

The report doesn't mention any side effects, serious adverse events, or discontinuations. That doesn't mean there were none; it just means the information wasn't included. Always ask your doctor about potential risks of any treatment.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
ObjectiveTo delineate the clinical characteristics, diagnostic criteria, therapeutic strategies, and prognosis of myasthenia gravis (MG) with thymoma-associated CRMP5/CV2 antibody-positive paraneoplastic neurological syndrome (PNS), thereby enhancing clinical recognition of this rare overlapping autoimmune disorder.MethodsWe retrospectively analyzed the clinical data of a 53-year-old male patient presenting with peripheral nerve injury as the initial manifestation, who was subsequently diagnosed with MG, invasive thymoma, and CRMP5/CV2 antibody-positive PNS. A comprehensive review of the relevant international literature was also conducted.ResultsThe patient had a 2-year disease course, initially presenting with limb numbness and unsteady gait, and gradually developing dysarthria, dysphagia, diplopia, and myasthenic weakness with characteristic diurnal fluctuation (worsening in the evening and improving in the morning). According to the Myasthenia Gravis Foundation of America (MGFA) clinical classification, the patient was categorized as Class IIIb (moderate generalized MG with predominant oropharyngeal involvement) at baseline. Serological tests confirmed positive for acetylcholine receptor (AChR) antibody in serum, as well as CRMP5/CV2 antibody in both serum and cerebrospinal fluid (CSF). Electrophysiological examinations revealed multiple peripheral nerve damage and a significant decremental response to low-frequency repetitive nerve stimulation (RNS). Chest CT demonstrated an invasive thymoma in the anterior mediastinum. The patient underwent thoracoscopic thymectomy, followed by sequential treatment with glucocorticoids, intravenous immunoglobulin and cyclophosphamide, as well as symptomatic supportive care and anti-infective management. After treatment, the neurological symptoms were significantly improved, and the condition remained stable during follow-up.ConclusionMG with thymoma-associated CRMP5/CV2 antibody-positive PNS represents a rare clinical entity with atypical onset and is highly susceptible to misdiagnosis. Combined detection of paraneoplastic antibodies and chest imaging is critical for early diagnosis, and thymectomy combined with standardized immunotherapy can effectively improve the clinical symptoms and long-term prognosis of patients.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.